Overview

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

Status:
Completed
Trial end date:
2013-09-19
Target enrollment:
Participant gender:
Summary
This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride
Details
Lead Sponsor:
Shire
Treatments:
Anagrelide